Haylard Health eyes sale of surgical, infection prevention unit

Halyard Health, a medical products supplier, seeks to divest its surgical and infection prevention business, unnamed sources told Reuters.

Halyard Health hired investment bank Deutsche Bank to launch a sales process for the unit, sources told Reuters Monday. The sources — who note sales talks do not guarantee a divestiture — said a deal could be worth more than $600 million, according to the report.

The surgical and infection prevention unit represents Halyard Health's largest business in terms of revenue, posting about $1 billion in sales for 2016. However, the unit's sales have decreased year-over-year, limiting the company's growth, reports Reuters. The divestiture would allow Haylard Health to shift focus away from hospital products to its medical device unit, which saw a 15 percent sales growth in the most recent quarter.

Halyard Health and Deutsche Bank did not immediately respond to Reuters' request for comment.

More articles on supply chain:

Drug costs fluctuate by more than 600% worldwide: 4 study findings
SCOTUS ruling brings biosimilars to market faster: 4 things to know
Cancer drugs may be just as effective — and cheaper — at lower doses, oncologists say

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars